Company Named After Medieval German Hero Wants Drug Import License
Published Date: 11/26/2025
Notice
Summary
Siegfried Grafton, Inc. wants to become an official importer of certain controlled substances like marijuana and gamma hydroxybutyric acid. People and companies involved can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Application to Import Schedule I Substances
Siegfried Grafton, Inc. applied on September 1, 2025 to be a federal importer for the Schedule I substances gamma hydroxybutyric acid (GHB), marihuana extract, marihuana, MDMA (3,4-methylenedioxymethamphetamine), and dimethyltryptamine (DMT). If registered, the company would be authorized to import those substances only for analytical testing or distribution. Interested parties may submit comments or request a hearing by December 26, 2025.
Import Restriction: No Finished Dosage Forms
The DEA notice states that any importer registration will not authorize the import of Food and Drug Administration (FDA)-approved or non-approved finished dosage forms for commercial sale. That means import permission would be limited to non-finished forms (e.g., bulk material) and not permit bringing finished commercial drug products into the U.S.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-21177 — Importer of Controlled Substances Application: Halo Pharmaceutical Inc.
Halo Pharmaceutical Inc. wants to become an official importer of certain controlled substances, including psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances enter the U.S., so keep an eye on the deadline to have your say!
Next: 2025-21179 — Importer of Controlled Substances Application: Caligor Coghlan Pharma Services
Caligor Coghlan Pharma Services wants to become an official importer of certain controlled substances, including some powerful drugs like LSD. People and companies involved with these drugs can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances are brought into the U.S., but no costs or fees are mentioned yet.